We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.58B
AUM Growth
+$232M
Cap. Flow
+$52.5K
Cap. Flow %
0%
Top 10 Hldgs %
43.75%
Holding
149
New
7
Increased
20
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$60.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
VTRS icon
Viatris
VTRS
+$16.7M
4
MCK icon
McKesson
MCK
+$14.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$13.3M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$28.8M
2
MDCO
Medicines Co
MDCO
+$26.2M
3
INCY icon
Incyte
INCY
+$23.8M
4
ABT icon
Abbott
ABT
+$18.6M
5
CNC icon
Centene
CNC
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.08%
2 Real Estate 3.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
76
DELISTED
Avadel Pharmaceuticals
AVDL
$6.04M 0.23%
624,288
– –
DXCM icon
77
DexCom
DXCM
$28.8B
$6.03M 0.23%
+284,800
New +$5.56M
UHS icon
78
Universal Health Services
UHS
$9.88B
$6M 0.23%
48,180
-98,600
-67% -$11.7M
RARE icon
79
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.99M 0.23%
88,400
– –
UTHR icon
80
United Therapeutics
UTHR
$26.2B
$5.95M 0.23%
43,961
-49,139
-53% -$7.44M
SNR
81
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$5.79M 0.22%
567,997
– –
HCA icon
82
HCA Healthcare
HCA
$85.7B
$5.64M 0.22%
63,432
-126,800
-67% -$10.6M
DERM
83
DELISTED
Dermira, Inc.
DERM
$5.63M 0.22%
165,200
– –
EW icon
84
Edwards Lifesciences
EW
$50B
$5.26M 0.2%
+167,700
New +$5.25M
MYOV
85
DELISTED
Myovant Sciences Ltd.
MYOV
$4.7M 0.18%
400,000
– –
FOMX
86
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.61M 0.18%
930,398
– –
BLUE
87
DELISTED
bluebird bio
BLUE
$4.49M 0.17%
3,809
– –
AGN.PRA
88
DELISTED
Allergan plc
AGN.PRA
$4.25M 0.16%
5,000
– –
INVA icon
89
Innoviva
INVA
$1.57B
$3.44M 0.13%
+248,803
New +$2.93M
AFMD
90
DELISTED
Affimed
AFMD
$3.23M 0.13%
140,532
+111,111
+378% +$2.44M
ONC
91
BeOne Medicines Ltd
ONC
$33.4B
$3.21M 0.12%
87,531
-29,176
-25% -$1.06M
GRFS
92
Grifois
GRFS
$5.58B
$3.13M 0.12%
166,000
– –
TVTX icon
93
Travere Therapeutics
TVTX
$5.33B
$3.1M 0.12%
167,949
– –
FOLD
94
DELISTED
Amicus Therapeutics
FOLD
$2.99M 0.12%
418,730
– –
THC icon
95
Tenet Healthcare
THC
$21.8B
$2.91M 0.11%
164,500
– –
NVO
96
Novo Nordisk
NVO
$228B
$2.85M 0.11%
+166,000
New +$2.89M
NBRV
97
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.8M 0.11%
933
-467
-33% -$1.14M
MNK
98
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$2.76M 0.11%
61,900
– –
FWP
99
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.64M 0.1%
17,548
-1,959
-10% -$369K
HALO icon
100
Halozyme
HALO
$9.88B
$2.59M 0.1%
200,000
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Tekla Capital Management held 149 positions worth $2.58B, up 9.9% from $2.35B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q1 2017 filing shows 7 new, 20 increased, 25 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M. The largest sale was Allergan plc, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2017 buy was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M.
  • Tekla Capital Management added most to Amgen in Q1 2017, an estimated $60.3M increase.
  • Tekla Capital Management's biggest Q1 2017 reduction was Allergan plc, cutting an estimated $28.8M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2017, selling an estimated $26.2M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.58B portfolio in Q1 2017.
  • Tekla Capital Management opened 7 new positions and closed 10 in Q1 2017.
  • Tekla Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.58B.

Based on Tekla Capital Management's 13F filing for Q1 2017, filed 12 May 2017.